Japan-based Astellas has promoted David Abbott as its national vice president, Key Account Management, it was announced yesterday.
Abbott's earlier role was senior director of Key Account Management for the company's Oncology franchise. Based in Massachusetts, Abbott has more than 20 years of biopharma experience, previously serving as national access director at AVEO Oncology. He also worked at Sanofi and Sanofi Genzyme, including as regional sales manager for Hospital and Oncology, Oncology Access & Reimbursement account manager, and director of Multiple Sclerosis Payer and Channel Marketing. Abbott joined Astellas in 2013.
Abbott will now manage teams who work with large healthcare organizations to provide educational resources and tools that help customers identify, educate and treat patients.
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Frontage expands early phase clinical research capabilities across US and China
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
InSysBio agrees new collaborative project with BeOne Medicines
Physiomics secures new modelling contract with Numab Therapeutics
Mabwell reports first patient dosed with 7MW4911 in US trial
Atossa Therapeutics' founder and CEO named one of The Top 50 Healthcare Technology CEOs of 2025
Avacta secures FDA clearance for second pre|CISION oncology programme
Guardant Health and Merck enter multi-year oncology diagnostics collaboration
Akeso secures NMPA review acceptance for gumokimab in ankylosing spondylitis